Merck’s Keytruda combo gets US FDA approval for gastric cancer
Merck, referred to as MSD outside of the US and Canada, has announced that its Keytruda (pembrolizumab) plus chemotherapy has been approved by the US Food and Drug
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XMerck, referred to as MSD outside of the US and Canada, has announced that its Keytruda (pembrolizumab) plus chemotherapy has been approved by the US Food and Drug
LENZ Therapeutics, a biopharmaceutical company in the late stages of development, specialising in advancing and bringing innovative vision-improving therapies to market, has signed a definitive agreement to merge
Almirall, a biopharmaceutical company specialising in medical dermatology, has entered into a significant drug discovery partnership with Absci, an AI-driven drug creation company. The collaboration represents a significant
Charles River Laboratories International and Aitia have entered into a strategic agreement, allowing Aitia access to Logica, Charles River’s artificial intelligence (AI) powered drug discovery solution. Aitia will
GenScript ProBio and Curocell have entered into a strategic partnership memorandum of understanding (MoU) to collaborate on the production of viral vectors essential for the development of the
Novartis has reported positive data from the Phase III REMIX-1 and REMIX-2 studies evaluating remibrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, in individuals with chronic spontaneous urticaria
Alfasigma through its wholly-owned subsidiary Interstellar Acquisition has completed the acquisition of Intercept Pharmaceuticals. The acquisition involved a tender offer to purchase all outstanding shares of common stock
Huma Therapeutics, a global digital health company, has joined forces with Merck KGaA, Darmstadt, Germany, to develop a digital solution aimed at enhancing the understanding and management of
Landmark Bio has entered into a multi-year strategic manufacturing agreement with Galapagos, a biotechnology company known for its innovative operations in Europe and the US. Under the terms
Biotheus has signed an exclusive global license and collaboration deal with BioNTech under which BioNTech will take on the development, manufacturing, and commercialisation of PM8002 on a global